Holen Sie sich die Stockscreener-App
258.07
4.76%
11.73
Schlusskurs vom Vortag:
$246.34
Offen:
$266
24-Stunden-Volumen:
2.07M
Relative Volume:
2.44
Marktkapitalisierung:
$18.15B
Einnahmen:
$2.36B
Nettoeinkommen (Verlust:
$236.10M
KGV:
78.54
EPS:
3.286
Netto-Cashflow:
$382.50M
1W Leistung:
+2.88%
1M Leistung:
-10.30%
6M Leistung:
-20.12%
1J Leistung:
-8.07%
1-Tages-Spanne:
$256.62
$275.10
1-Wochen-Bereich:
$240.78
$275.10
52-Wochen-Spanne:
$230.05
$354.88
Insulet Corporation Stock (PODD) Company Profile
Firmenname
Insulet Corporation
Sektor
Branche
Telefon
978-600-7000
Adresse
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
258.07 | 17.33B | 2.36B | 236.10M | 382.50M | 3.286 |
|
ABT
Abbott Laboratories
|
113.29 | 195.21B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
377.32 | 141.28B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
98.49 | 123.60B | 35.48B | 4.64B | 5.41B | 3.5856 |
|
BSX
Boston Scientific Corp
|
76.28 | 113.14B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
78.98 | 45.52B | 6.07B | 1.06B | 799.60M | 1.8527 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Fortgesetzt | TD Cowen | Hold |
| 2026-01-12 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-16 | Eingeleitet | Evercore ISI | Outperform |
| 2025-11-19 | Hochstufung | UBS | Neutral → Buy |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-05-13 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-07 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-08-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-07-28 | Eingeleitet | Wells Fargo | Overweight |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-03-31 | Herabstufung | Berenberg | Buy → Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-10 | Eingeleitet | CFRA | Sell |
| 2019-10-23 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-10-04 | Herabstufung | UBS | Buy → Neutral |
| 2019-10-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-04-20 | Eingeleitet | Berenberg | Buy |
| 2018-02-22 | Bestätigt | Barclays | Overweight |
| 2018-01-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Insulet Corporation Aktie (PODD) Neueste Nachrichten
Decoding Insulet Corp (PODD): A Strategic SWOT Insight - GuruFocus
BTIG reiterates Insulet stock rating on strong Q4 results - Investing.com Nigeria
Canaccord Genuity lowers Insulet stock price target on valuation - Investing.com
Insulet Corporation (PODD) PT Lowered to $435 at Canaccord Genuity - StreetInsider
PODD: BTIG Reiterates Buy Rating with $380 Price Target | PODD S - GuruFocus
INSULET CORP SEC 10-K Report - TradingView
Insulet Corp (PODD) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Insulet stock rises before hours on Street-beating Q4, 31% sales growth - MassDevice
Insulet Corp (PODD) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Innovations - GuruFocus
Insulet's (PODD) "Buy" Rating Reiterated at BTIG Research - MarketBeat
Insulet Shares Rise After Q4 Results Beat - marketscreener.com
Insulet Corp (PODD) Trading 6.2% Higher on Feb 18 - GuruFocus
BTIG Reiterates Buy Rating on Insulet Corporation (PODD) - StreetInsider
Insulet Reports Fourth Quarter and Full Year 2025 Results - BioSpace
Insulet (PODD) Shares Skyrocket, What You Need To Know - Finviz
Insulet stock gains on Q4 2025 print, outlook (PODD:NASDAQ) - Seeking Alpha
User - The Chronicle-Journal
Earnings call transcript: Insulet’s Q4 2025 revenue beats forecast, stock surges - Investing.com Nigeria
Insulet (NASDAQ:PODD) Shares Gap Up Following Strong Earnings - MarketBeat
Insulet Q4 2025 slides: revenue soars 31%, stock jumps on strong 2026 outlook - Investing.com
Insulet Corporation Reports 31% Annual Revenue Growth; Authorizes $350 Million Repurchase Increase - AlphaStreet News
Insulet Q4 Earnings Call Highlights - Yahoo Finance
Insulet (PODD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo! Finance Canada
Insulet Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Insulet (PODD) Projects Significant Growth in Q1 Omnipod Revenues - GuruFocus
Insulet (PODD) Projects Significant Revenue Growth by FY26 - GuruFocus
Insulet (PODD) Surpasses Q4 Revenue Expectations with Strong Res - GuruFocus
Sector Update: Health Care - marketscreener.com
Global Payments, Insulet, and SolarEdge Report Q4 2025 Earnings - Tokenist
Medical Device Company Exceeds Expectations with Insulin Pump Sales Growth - Fine Day 102.3
Insulet (NASDAQ:PODD) Surprises With Q4 CY2025 Sales - Finviz
Insulet (PODD) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
Insulet: Q4 Earnings Snapshot - KVUE
Insulet Corporation Provides Earnings Guidance for the First Quarter Ending March 31, 2026 and Year Ending December 31, 2026 - marketscreener.com
Insulet Q4 and Full-Year Financial Results: Earnings Beat Analyst ForecastsNews and Statistics - IndexBox
Insulet beats quarterly estimates on strong demand for wearable insulin pumps - marketscreener.com
Insulet: Fourth Quarter Financial Overview - Bitget
Insulet Posts Strong Q4 Results, Expands Share Repurchase Program - TipRanks
INSULET ($PODD) Releases Q4 2025 Earnings - Quiver Quantitative
Insulet Corp. Q4 Sales Increase - Nasdaq
Insulet beats revenue expectations in fourth quarter, shares rise By Investing.com - Investing.com Canada
Earnings Flash (PODD) Insulet Corporation Reports Q4 Revenue $783.8M, vs. FactSet Est of $769.0M - marketscreener.com
What Are Wall Street Analysts' Target Price for Insulet Stock? - Barchart.com
Insulet beats revenue expectations in fourth quarter, shares rise - Investing.com
Earnings Summary: Insulet Q4 - Benzinga
Insulet earnings in focus as Omnipod growth faces new test By Investing.com - Investing.com Australia
Insulet earnings in focus as Omnipod growth faces new test - Investing.com India
Insulet Corp (NASDAQ:PODD): A Prime GARP Candidate in Diabetes Care - ChartMill
Insulet Corporation (NASDAQ:PODD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Earnings To Watch: Insulet (PODD) Reports Q4 Results Tomorrow - The Globe and Mail
Aberdeen Group plc Has $47.80 Million Stock Holdings in Insulet Corporation $PODD - MarketBeat
Finanzdaten der Insulet Corporation-Aktie (PODD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):